Bayer boss defends Monsanto takeover despite lawsuits
Company faces 11,200 US cases over weedkiller Roundup and has been ordered to pay $78.5m to one claimant
Frankfurt — The boss of German chemicals giant Bayer insists its multibillion-dollar takeover of Monsanto is a “good idea”, despite huge legal costs piling up over its Roundup weedkiller.
“The Monsanto acquisition was and is a good idea,” Werner Baumann told newspaper Frankfurter Allgemeine Sonntagszeitung on Sunday, when asked if he would have changed his mind about buying the US group if he could.
Bayer bought Monsanto for $63bn but the deal has turned out to be plagued with other enormous costs.
Just two months after the acquisition was completed, Monsanto lost a case to a school groundskeeper suffering from terminal non-Hodgkin’s lymphoma, who had sued the company over the glyphosate weedkillers Roundup and Ranger Pro.
Monsanto was initially ordered to pay $289m to Dewayne Johnson, before the damages were reduced to $78.5m.
Bayer has filed an appeal.
The company suffered a new setback in March as a US jury ruled that Roundup was a “substantial factor” in another case brought by an amateur gardener who was suffering from cancer.
It now faces a total of 11,200 US cases over Roundup and its active ingredient glyphosate, a herbicide key to Monsanto’s business model that has come in for intense scrutiny around the world.
Werner insisted the acquisition of Monsanto was carried out after careful due diligence.
Bayer has also pointed to findings from regulators around the world, especially in advanced economies such as the US, Europe and Canada, and reams of scientific studies as proof of the safety of its product.
“Regulatory authorities around the world consider glyphosate-based herbicides as safe when used as directed,” the group has argued, highlighting “800 rigorous studies” of glyphosate’s effects.
The World Health Organisation’s international agency for research on cancer found in 2015 that glyphosate is “probably carcinogenic”, though the European Food Safety Authority and the European Chemicals Agency have not issued similar judgments.
Since the Monsanto takeover was completed, Bayer’s stock has shed almost 40% of its value.